Frederique Menzaghi, Ph.D., Chief Scientific Officer and SVP of Research & Development, will depart the Company, effective February 2, 2024.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CARA:
- Biotech Alert: Searches spiking for these stocks today
- Cara Therapeutics price target lowered to $2.50 from $7 at H.C. Wainwright
- Cara Therapeutics expects to end 2023 with $100M in cash
- Cara Therapeutics to discontinue clinical program in pruritus associated with AD
- Cara Therapeutics Announces Outcome from Dose-Finding Part A of KIND 1 Study Evaluating Oral Difelikefalin for Moderate-to-Severe Pruritus in Patients with Atopic Dermatitis
